219783-74-1

Basic information

• Product Name: 2,3-dimethylbenzohydrazide(SALTDATA: FREE)
• Synonyms: 2,3-dimethylbenzohydrazide(SALTDATA: FREE)
• CAS NO: 219783-74-1
• Molecular Formula: C₉H₁₂N₂O
• Molecular Weight: 164.20438
• Mol File: 219783-74-1.mol

Chemical Properties

• Appearance: /
• Density: 1.098g/cm³
• Refractive Index: 1.561
• PKA: 12.80±0.10(Predicted)
• CAS DataBase Reference: 2,3-dimethylbenzohydrazide(SALTDATA: FREE)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-dimethylbenzohydrazide(SALTDATA: FREE)(219783-74-1)
• EPA Substance Registry System: 2,3-dimethylbenzohydrazide(SALTDATA: FREE)(219783-74-1)

Safety Data

• Hazardous Substances Data: 219783-74-1(Hazardous Substances Data)

Usage

Uses

Used in Polymer and Coating Industries:
2,3-dimethylbenzohydrazide(SALTDATA: FREE) is used as a stabilizer and inhibitor for enhancing the performance and extending the shelf life of polymers and coatings. It effectively prevents the degradation of these materials, ensuring their durability and longevity.
Used as a Radical Scavenger:
In certain chemical reactions, 2,3-dimethylbenzohydrazide(SALTDATA: FREE) is used as a radical scavenger. Its ability to neutralize radicals contributes to the stability and control of these reactions, preventing unwanted side effects and improving the overall efficiency of the process.
Used as a Photostabilizer in Plastics and Coatings:
2,3-dimethylbenzohydrazide(SALTDATA: FREE) is utilized as a photostabilizer in plastics and coatings to protect them from the harmful effects of ultraviolet (UV) radiation. By absorbing and dissipating UV energy, it prevents the degradation and discoloration of these materials, maintaining their appearance and functionality over time.

InChI:InChI=1/C9H12N2O/c1-6-4-3-5-8(7(6)2)9(12)11-10/h3-5H,10H2,1-2H3,(H,11,12)

Upstream product

• 104175-24-8 ethyl 2,3-dimethylbenzoate 
• 603-79-2 2,3-dimethylbenzoic acid 

Relevant articles and documents

Synthesis, characterization and bioactivity studies of novel 1,3,4-oxadiazole small molecule that targets basic phospholipase A2 from Vipera russelli

Secretory phospholipase A2 (sPLA2) is a key enzyme participating in the inflammatory cascade followed by the action of cyclooxygenase-2 and lipoxygenases. Therefore, inhibitors of sPLA2 could be used as potent anti-inflammatory agents to treat the early phase of inflammation. In this study, we have prepared the fenoprofen and ibuprofen analogs containing 1,3,4-oxadiazole nucleus and tested against Vipera russelli venom's basic sPLA2 (VRV-PL-VIIIa). Among the tested ligands 5(a–t),2-(2-chlorophenyl)-5-(1-(4-phenoxyphenyl) ethyl)-1,3,4-oxadiazole (5m) inhibited the catalytic activity of VRV-PL-VIIIa with an IC50 value of 11.52?μM. Biophysical studies revealed that the 5m quenches the intrinsic fluorescence of VRV-PL-VIIIa, in a concentration dependent manner. Also, the compound 5m affected VRV-PL-VIIIa conformation, which was observed by circular dichroism spectra that recorded the prominent shift in the α-helix peak and the random coil formation of VRV-PL-VIIIa. Further, molecular docking analysis revealed that the compound 5m possess strong hydrophobic interactions at catalytic triad region of the VRV-PL-VIIIa. Evident to in vitro and in silico studies, 5m strongly inhibited the hemolysis of red blood cells. Our in vivo pharmacological studies revealed that the compound 5m inhibited the edematogenic activity of VRV-PL-VIIIa in?mouse foot pad. Additionally, the 5m inhibited VRV-PL-VIIIa-induced myotoxicity and lung hemorrhage in mice. Overall, our ADMET results depicted that 5m possess better druggable property. Thus, this study explored the new fenoprofen and ibuprofen analog 5m as the lead-structure that serves as an anti-inflammatory agent.

Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex

The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.